Cambridge Healthtech Institute’s Second Annual
Adoptive T Cell Therapy
Techniques and Strategies for Cell Therapy Discovery and Development
Part of the 11th Annual PEGS: the essential protein engineering summit
May 6-7, 2015 | World Trade Center | Boston, Ma


Recent advances in protein engineering and molecular biology have increased the feasibility of using genetically engineered T cells to treat disease, leading to an influx of new discoveries and techniques. With these new treatments becoming ready for prime-time, researchers will need to increase their discovery efforts to meet patient need and continue advancing the field. Cambridge Healthtech Institute's second annual Adoptive T Cell Therapy will review the latest strategies for target discovery, as well as T cell receptors (TCRs), chimeric antigen receptors (CAR), and tumor infiltrating lymphocytes (TILs) against tumor antigens. This event will focus on issues facing the field with an emphasis on engineered T cells and the use of adoptive T cell transfer to facilitate therapeutic treatments for cancer, infectious diseases, and bone marrow transplants. Clinical data will be showcased, as well as in depth examinations of where the field is headed.


PROMISING ANTI-CANCER THERAPEUTICS: CAR, TCR, and TIL 

The Principles of Chimeric Antigen Receptor Design

Michel Sadelain, M.D., Ph.D., Director, Center for Cell Engineering & Gene Transfer and Gene Expression Laboratory; Stephen and Barbara Friedman Chair, Memorial Sloan-Kettering Cancer Center

Affinity-Enhanced TCRs for Adoptive T Cell Therapy

Gwendolyn Binder-Scholl, Executive Vice President & Head, Clinical and Regulatory Development, Adaptimmune

Autologous Tumor-Infiltrating Lymphocyte (TIL) Therapy

Laszlo Radvanyi, Ph.D., CSO, Lion Biotechnologies

PANEL DISCUSSION: CAR vs. TCR vs. TIL

Panelists: Speakers from previous session


PREDICTING AND PREVENTING TOXICITY 

Ensuring the Safety of Cellular Therapy

Malcolm K. Brenner, MB, Ph.D., Founding Director, Professor, Center for Cell and Gene Therapy, Baylor College of Medicine

Engineering the Immune Response to “Self” for Effective Adoptive T Cell Therapy

Michelle Krogsgaard, Ph.D., Assistant Professor, New York University Perlmutter Cancer Center, New York University School of Medicine

Mechanisms of Efficacy and Acute Toxicity after Adoptive CAR T Cell Treatment

Charles Sentman, Ph.D., Professor, Microbiology & Immunology, Geisel School of Medicine

In vivo Functionality of Immune Cells Engineered via Vector-Free Intracellular Delivery

Armon Sharei, Ph.D., Founder, SQZ Biotech


TARGET DISCOVERY AND ANTIGEN SELECTION 

Novel Cancer Targets for Adoptive Cellular Therapy

Harpreet Singh, Ph.D., CSO and Managing Director, immatics biotechnologies GmbH

Optimization of Engineered T Cell Products based on Clinical Performance versus Pharmacodynamics Markers: Where Do We Stand?

Adrian Bot, M.D., Ph.D., Vice President, Translational Medicine, Kite Pharma, Inc.


TARGETING SOLID TUMORS 

Optimization of T Cell Production Process for Adoptive T Cell Therapy

Pranay Khare, Ph.D., Director, Cancer Immunotherapy and Gene Therapy cGMP Facility, Roger Williams Medical Center


For more details on the conference, please contact:
Samantha Lewis
Conference Producer
Cambridge Healthtech Institute
T: 781-972-5461
E: slewis@healthtech.com 

For partnering and sponsorship information, please contact:
Jason Gerardi (Companies A-K)
Manager, Business Development
Cambridge Healthtech Institute
T: 781-972-5452
E: jgerardi@healthtech.com 

Carol Dinerstein (Companies L-Z)
Director, Business Development
Cambridge Healthtech Institute
T: 781-972-5471
E: dinerstein@healthtech.com